From a translational perspective, PTM-informed NF-κB inhibition offers several therapeutic opportunities: 1) In inflammation-driven cancers such as colorectal, gastric, and pancreatic cancer, targeting PTM-mediated NF-κB hyperactivation may suppress immune evasion and prevent malignant transformation. This evidence concerns the gene NFKB1 and familial pancreatic carcinoma.